License of Technology Clause Samples
POPULAR SAMPLE Copied 1 times
License of Technology. Simultaneous with the issuance and exchange of the Investment Shares, as set forth in Article III and the Exchange as set forth in Article V, Cardiotech shall grant, convey and provide (“Technology License”) to CorNova an exclusive license, subject to customary terms and conditions to be set forth in a separate license agreement (the “License”), for the technology consisting of Chronoflex DES polymer or any poly (carbonate) urethane containing derivative thereof for use on drug-eluting stents (collectively the “Technology”).
License of Technology. Subject to certain terms and conditions, LICENSOR hereby grants to LICENSEE each of the licenses more fully defined in Section 2 below.
License of Technology. Subject to the terms and conditions of this Agreement, LICENSOR hereby grants to LICENSEE a semi-exclusive (as defined in Section 2 below), non-transferable, non-sub-licensable, license to use the Technology to develop, test, make, sell, offer for sale and distribute the End Products during the Term of this Agreement. Notwithstanding the first sentence of this paragraph, LICENSEE is expressly permitted to sub-license its license to use the Technology to a Partner or to Related Entities (all as defined in Exhibit D). Provided also that in the event that a person acquires all of the issued and outstanding shares of LICENSEE, or all or substantially all of the assets of the LICENSEE, the LICENSEE shall be entitled to transfer all of its rights and obligations relating to this agreement to such person, and such person is entitled to all of the rights and benefits of the LICENSEE under this agreement with respect to End Products then being sold or produced by the LICENSEE on its own behalf or as a contract manufacturer.
License of Technology. Subject to the terms and conditions of this Agreement, LICENSOR hereby grants to LICENSEE a limited license (as defined in Section 2 below), to use the Technology to develop, test, make, sell, offer for sale and distribute the End Products during the Term of this Agreement.
License of Technology. As additional consideration for the payments by PayCell recited herein, CLTR and CreditPipe shall enter into a new license for PayCell’s worldwide use (excepting the African continent) of all CreditPipe technology, which shall supersede that license agreement between the parties dated May 16, 2004.
License of Technology. For purposes of this Exhibit A - Scope of Work, the site address is: 100302 ▇▇▇▇▇ Well Road Nipton, CA 92366 Or, for United States Postal Service deliveries only: HCR I, ▇▇▇ ▇▇▇ ▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ SRSG Recommended Spare Parts List2 Material Size Qty Exclusive Spare Parts Non-Exclusive Spare Parts3 Superheater Panel -[*] Tubes 1 [*] [*] Superheater Panel -[*] Tubes 1 [*] [*] Reheater Panel -[*] Tubes 1 [*] [*] Steam Generator Panel -[*] 1 [*] [*] Pumps -[*] [*] 7 [*] [*] [*] 7 [*] [*] [*] 7 [*] [*] [*] Valves -one unit spares [*] [*] [*] 18 [*] [*] [*] [*] [*] 8 [*] [*] [*] [*] [*] 19 [*] [*] [*] [*] [*] 1 [*] [*] [*] [*] [*] 2 [*] [*] [*] [*] [*] 2 [*] [*] [*] 6 [*] [*] [*] 2 [*] [*] [*] 2 [*] [*] 2 Vendor shall (a) provide any additional spare parts prior to Mechanical Completion (as defined in the ECC) and the commencement of commissioning activities and (b) provide a list of additional spare parts to be delivered no later than three months prior to such delivery. 3 “Exclusive Spare Parts” and “Non-Exclusive Spare Parts” are as defined in the CGSA. * Confidential Treatment Requested Exhibit B Page 1 [*] one unit spares [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] * Confidential Treatment Requested Exhibit B Page 2 [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] Seal Kit [*] 8 [*] Actuators [*] 2 [*] [*] [*] 2 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 2 [*] [*] [*] 1 [*] [*] [*] 2 [*] [*] [*] 2 [*] [*] [*] 2 [*] [*] [*] 2 [*] [*] [*] 4 [*] [*] [*] 4 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] * Confidential Treatment Requested [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 4 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] Spare parts for [*] [*] 2 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 24 [*] [*] [*] 3 [*] [*] [*] 1 [*] [*] [*] 1 [*] [*] [*] 2 [*] [*] * Confidential Treatment Requested [*] 4 [*] [*] [*] 6 [*] [*] Gland Studs MFSS-3 6-16-2.125-B8M 4 [*] [*] Gland...
License of Technology. In the event CVD is unable, for any reason, to manufacture or deliver any quantities of any Components for Medtronic hereunder for a period in excess of ninety (90) days, CVD agrees that Medtronic shall be automatically granted a non-exclusive, fully paid up, non-sublicensable, worldwide license to all patents, technology and know-how necessary to make, use, and sell the Components for use or benefit of Medtronic. The license shall be for the earlier of the term of this Agreement or until CVD
License of Technology. Subject to the terms and conditions of this Agreement, and in consideration of the mutual covenants and promises contained herein, and for the Royalty recited herein, Licensor hereby grants to Licensee, for the term of this Agreement, a non-exclusive, non-transferable, right and license to practice the Technology, including the trade secrets, know-how, inventions, systems, methods therein, in the Number of Annual Tests.
License of Technology. 2.1 In consideration of the payment of Technology licensing fee, set forth in Section 2.2 hereof and the royalty payments set forth in Section 8 hereof, Faulding hereby licenses the Technology to Purepac for a period commensurate with the term of this Agreement, as set forth in Section 15 hereof, to use and take advantage of the Technology for the purposes of completing the development of the Product and manufacturing and selling the Product within the Territory during the term of this Agreement. Purepac management has been involved in the development of the Technology and understands that further development of the Technology is necessary for completion of the Product.
2.2 The parties agree that the Technology licensing fee shall aggregate $(U.S.)1,834,434 and, as the case may be, has been paid or shall be payable by Purepac to Faulding in three payments as follows:
(a) $(U.S.)1,234,434, which Purepac has heretofore paid Faulding in full;
(b) $(U.S.)350,000, payable on July 31, 1995; and
(c) $(U.S.)250,000, payable thirty (30) days after the Technology Transfer Date.
2.3 The license of the Technology pursuant to this Agreement is sole and exclusive for the development, manufacture, and sale of the Product in the Territory. Faulding agrees that it will not sell or transfer the Technology or grant any rights to use or exploit the Technology to any other person or corporation for the manufacture or distribution in the Territory of the Product or a product competitive with the Product during the term of this Agreement, but the parties understand and agree that Faulding has the right, subject to the limitations set forth in Section 4.3, to license the Technology outside the Territory for any purpose and within the Territory for any purpose other than the manufacture and distribution of a product competitive with the Product.
2.4 Purepac agrees that it will not use or exploit the Technology for any purpose other than the manufacture and sale of the Product in the Territory and that it will not manufacture, sell or attempt to sell the Product outside the Territory either on its own account or through any third party nor will it sell any Product to any person or corporation within the Territory where Purepac has reasonable grounds to believe that such other person or corporation intends to sell the Product outside the Territory.
2.5 In the event that either (a) Purepac submits a written request to Faulding to market the Product outside the Territory or (b) Fauldi...
License of Technology. Party C agrees to grant rights to its drug candidate MN-221 to the JV and related know-how, to the extent owned by or licensed to Party C, pursuant to the terms and conditions of a license agreement to be entered into between the JV and Party C, except that Party C is under no obligation to grant the JV access to know-how or other information provided to Party C by or on behalf of Kissei under Party C’s license with Kissei.